VivoSeq
Other

Hot Flashes

52

Pipeline Programs↗

6

Active Trials↗

28

Companies Involved↗

Hot flashes is a moderately active landscape with 52 programs across 28 companies. The most active players are Amgen, Neurim Pharmaceuticals Ltd., Arog Pharmaceuticals, Inc.. 5 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1Pacira Pharmaceuticals, Inc logo

Pacira Pharmaceuticals, Inc

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 2F

Fervent Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

52 of 54 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody12%Protein / enzyme12%

Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 98% of 56 pipeline programs.

Analysis

Trial Status

59

clinical trials

Completed46 · 78%
Terminated4 · 7%
Recruiting3 · 5%
Active, not recruiting3 · 5%
Unknown status3 · 5%

Clinical Trials

Trial Activity

59 trials

Hot Flashes and Neurovascular Function in Women
Recruiting·MMayo Clinic·N/A·NCT05193968·120 enrolled
REDucing Hot FLASHes in Women Using Endocrine Therapy.
Recruiting·RReinier de Graaf Groep·Phase 3·NCT06106529·260 enrolled
Time-Efficient Inspiratory Muscle Strength Training for Reducing Sympathetic Activity and Improving Sleep in Midlife Women
Recruiting·MMayo Clinic·Preclinical·NCT06743269·30 enrolled
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Active, not recruiting·Astellas logoAstellas·N/A·NCT06049797·999 enrolled
A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause
Active, not recruiting·Astellas logoAstellas·N/A·NCT07455812·105 enrolled
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
Active, not recruiting·Astellas logoAstellas·Phase 3·NCT06440967·982 enrolled
Evaluation of SAMe for Hot Flashes
Completed·MMayo Clinic·Phase 2·NCT01140646·45 enrolled
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause
Completed·Astellas logoAstellas·Phase 3·NCT04234204·302 enrolled
Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer
Completed·VVirginia Commonwealth University·Phase 2·NCT01008904·31 enrolled
Impact of Hot Flashes on Sleep and Mood Disturbance
Completed·MMassachusetts General Hospital·Phase 4·NCT01116401·29 enrolled
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Completed·Bayer logoBayer·Phase 3·NCT05030584·628 enrolled
Study of Erenumab (AMG 334) in Women With Hot Flashes
Completed·Amgen logoAmgen·Phase 1·NCT01890109·103 enrolled
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
Completed·GSK logoGSK·Phase 2·NCT00604825·356 enrolled
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Completed·Astellas logoAstellas·Phase 2·NCT03192176·356 enrolled
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
Completed·Astellas logoAstellas·Phase 3·NCT04003155·527 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)